Prognostic value of integrated liquid biopsies in patients (pts) with metastatic urothelial cancer (mUC).
Charlotte N. Stahlfeld(University of Wisconsin–Madison), Joshua M. Lang(University of Wisconsin–Madison), Petros Grivas(Seattle Cancer Care Alliance), Moshe Chaim Ornstein(Cleveland Clinic), Yue Shi(University of Wisconsin–Madison), Rory M. Bade(University of Wisconsin–Madison), Jamie M. Sperger(University of Wisconsin–Madison), Caroline Burkey(UW Health University Hospital), Amy K. Taylor(University of Wisconsin–Madison), Shuang G. Zhao(University of Wisconsin Carbone Cancer Center), Jennifer L. Schehr(University of Wisconsin–Madison), Iris Yeong- Fung Sheng(Mount Auburn Hospital), Katherine R. Kaufmann(University of Wisconsin–Madison), Hamid Emamekhoo(University of Wisconsin Carbone Cancer Center)
Cited by 1
Related Papers
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|2.2k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2019|1.6k
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
|New England Journal of Medicine|2020|1.5k